Afluria® is distributed in the United States by CSL Biotherapies, the vaccine company of
CSL Limited, and one of the few providers of flu vaccines in the world today. With 40
years of influenza vaccine manufacturing and distribution experience, CSL Limited has
developed extensive expertise and plays a central role in helping to reduce the risk of
flu epidemics in many countries. Being a reliable influenza vaccine supplier comes from
not only our extensive expertise and knowledge, but also our relentless dedication
to the patients we serve.
Afluria® Influenza Virus Vaccine is a sterile suspension prepared from influenza
virus, which is propagated in the allantoic fluid of embryonic chicken eggs.
Following harvest, the virus is purified in a sucrose density gradient using a continous
flow zonal centrifuge. The purified virus is inactivated with beta propiolactone,
and the virus particles are disrupted using sodium taurdeoxycholate to produce a
"split virion." The disrupted virus is further purified and suspended
in a phosphate-buffered isotonic solution.
A purified, inactivated, split virion influenza vaccine, the vaccine is made by “splitting” the
purified, inactivated, whole virus to form fragments. This process reduces
the number of adverse events experienced with whole virus vaccines, yet leaves the surface
antigens and structural proteins in their original antigenic form.
Why choose Afluria
®?
- Reliable availability throughout the flu season
- Thimerosal-free (mercury-free) in a convenient latex-free prefilled syringe, or
- Multi-dose vial containing thimerosal as a preservative
and latex-free formulation
- Trusted influenza vaccine manufacturer with 40 years experience
- Indicated for adults 18 years and older
Afluria® is standardized according to United States Public Health Service (USPHS)
requirement for the 2007-2008 influenza season and contains no less than 15 mcg
hemagglutinin per dose for each of the 3 influenza strains recommended for the 2007-2008
US winter influenza season. The strains for this season include the
following1:
- An A/Solomon Islands/3/2006 (H1N1)-like virus1
- An A/Wisconsin/67/2005 (H3N2)-like virus1
- A B/Malaysia/2506/2004-like virus1
REFERENCES:
- Fiore AE, Shay DK, Haber P, et al. Prevention and control of influenza:
recommendations of the Advisory Committee on Immunization Practices. MMWR. 2007;56
(Early Release):1-54.